Skip to content

PHARMELLE

Active
Private limited companyfounded 20205 yrs activeWeggevoerdenstraat 20, 9300 Aalst, BelgiumKBO/BCE: BE 0760.602.338

The computed 12-month bankruptcy probability of PHARMELLE is 1.7% (moderate). The 2025 annual accounts show equity of €10k and a net result of €7k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 39% of 18207 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.

Checked score

Score 2025
59 / 100
Fair
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability88▼-4
Solvency46▼-54
Growth78=
Track record94
Bankruptcy probability, 12 months
1.7% Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €500 at 30 days acceptable
Liquidity tight (current ratio 1.23 against 5.3 in 2024; short-term debt: 78.6% and cash: 77.4% of total assets), and 78.6% of the assets are financed with debt.
Credit advice for your own amount and term

Signals

Five signals. The signal on the left, the evidence on the right.
+raises riskneutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation date
Age against the risk zone
elevated failure risk from 2 to 8 years 5 years 0 10 y
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 5 filings
Deviation from the deadline
2025
24 d early
2024
29 d early
2023
47 d early
2022
47 d early
2021
41 d early
← before the deadline after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
21-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Equity
€10k▼ 74.7%
2024 · €41k
2021: €6k 2022: €13k 2023: €32k 2024: €41k
2021 → 2025
Total assets
€49k▼ 3.8%
2024 · €51k
2021: €9k 2022: €17k 2023: €42k 2024: €51k
2021 → 2025
Net result
€7k▼ 20.4%
2024 · €9k
2021: €3k 2022: €7k 2023: €18k 2024: €9k
2021 → 2025
Working capital
€9k▼ 78.2%
2024 · €41k
2021: €6k 2022: €13k 2023: €31k 2024: €41k
2021 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Equity€6k-€13k▲ 119%€32k▲ 137%€41k▲ 29.3%€10k▼ 74.7%
Operating result€4k-€9k▲ 130%€24k▲ 150%€13k▼ 44.6%€12k▼ 10.6%
Net result€3k-€7k▲ 134%€18k▲ 152%€9k▼ 49.4%€7k▼ 20.4%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
€0€10k€20kOperating result 2021: €4k€4kNet result 2021: €3k€3kOperating result 2022: €9k€9kNet result 2022: €7k€7kOperating result 2023: €24k€24kNet result 2023: €18k€18kOperating result 2024: €13k€13kNet result 2024: €9k€9kOperating result 2025: €12k€12kNet result 2025: €7k€7k20212022202320242025
The operating result has fallen two years in a row; 2025 is 11% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €49k
Fixed assets €2k▲ 265%
Current assets €47k▼ 6.1%
Equity and liabilities €49k
Equity €10k▼ 74.7%
Debt €38k▲ 304%
The debt ratio rises from 18.7% to 78.6%. Equity is lower and debt is higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€12k
2024 · €13k
Cash flow
€8k
2024 · €10k
Solvency
21.4%
2024 · 81.3%
Current ratio
1.23
2024 · 5.30
Quick ratio
1.23
2024 · 5.30
Debt / equity
3.67
2024 · 0.23
ROE
71.2%
2024 · 22.6%
ROA
15.2%
2024 · 18.4%
Interest coverage
7.82
2024 · 39.88
Debt
€38k
2024 · €9k
Debt ≤ 1 year
€38k
2024 · €9k
Income taxes
€3k
2024 · €3k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet Code20242025
Assets
Total assets20/58€51k€49k
Fixed assets21/28€425€2k
Tangible fixed assets22/27€425€2k
Furniture and vehicles24€425€2k
Current assets29/58€50k€47k
Amounts receivable within one year40/41€1k€9k
Trade receivables40€0€8k
Other amounts receivable41€1k€895
Cash at bank and in hand54/58€49k€38k
Deferred charges and accrued income490/1€375€392
Equity and liabilities
Total equity and liabilities10/49€51k€49k
Equity10/15€41k€10k
Contributions10/11€3k€3k=
Profit (loss) carried forward14€38k€7k
Amounts payable17/49€9k€38k
Amounts payable within one year42/48€9k€38k
Trade debts44€77€0
Suppliers440/4€77€0
Taxes, remuneration and social security45€5k€864
Taxes450/3€5k€864
Other amounts payable47/48€4k€37k
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€278€474
Other operating charges640/8€864€1k
Gross operating margin9900€14k€13k
Operating profit (loss)9901€13k€12k
Financial charges65/66B€334€2k
Recurring financial charges65€334€2k
Profit (loss) for the period before taxes9903€13k€10k
Income taxes67/77€3k€3k
Profit (loss) for the period9904€9k€7k
Profit (loss) for the period to be appropriated9905€9k€7k
Appropriation of the result
Profit (loss) to be appropriated9906€38k€46k
Profit (loss) brought forward from the previous period14P€29k€38k
Profit to be distributed694/7-€38k
Return on contributions (dividend)694-€38k

The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
07-07
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
2025
02-07
NBB filing Annual accounts filed
fiscal year 2024 · micro schema
2024
14-06
NBB filing Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial Highest result since 2021net €18k ▲152%
Operating result €24k, net result €18k, both a record.
14-06
NBB filing Annual accounts filed
fiscal year 2022 · micro schema
2022
20-06
NBB filing Annual accounts filed
fiscal year 2021 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Aalst · 1 establishment unit since 2020
establishment The establishment unit on the map
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Weggevoerdenstraat 209300 Aalst
Ground area
226 m²
Building footprint
111 m²
Volume, LiDAR
527 m³
Parcel 41302C1101/00P004, Flanders · tallest building 9.8 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
PHARMELLE
Weggevoerdenstraat 20, 9300 AalstWholesale trade
since 20202.311.047.764
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
41302C1101/00P004 Flanders 226 m² 1 · 111 m² 9.8 m · 1 fl.
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Similar companies · same sector, comparable size

Of 5,222 companies in sector 47730 we hold annual accounts for 3,861. 846 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification
Legal formPrivate limited company
Founded28-12-2020
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
46150Agents in the wholesale of furniture, household goods and hardware
47740Retail trade
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
72101Research and development on biotechnology
72109Other research and development on natural sciences
Sources
Crossroads Bank for EnterprisesNational Bank · 5 filingsAddress and cadastre registers

Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.